$PCVX
Vaxcyte, Inc.

2020 Q4 Form 10-Q Financial Statement

#000156459020053540 Filed on November 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.790M $4.900M
YoY Change
% of Gross Profit
Research & Development $14.66M $16.41M $9.630M
YoY Change 9.57% 70.4%
% of Gross Profit
Depreciation & Amortization $340.0K $330.0K
YoY Change -46.03%
% of Gross Profit
Operating Expenses $19.45M $21.31M $12.14M
YoY Change 22.83% 75.52%
Operating Profit -$19.45M -$21.31M -$12.14M
YoY Change 22.83% 75.52%
Interest Expense -$1.610M -$500.0K $9.000K
YoY Change -5655.56%
% of Operating Profit
Other Income/Expense, Net -$1.284M $290.0K $823.0K
YoY Change -205.59% -64.76%
Pretax Income -$20.74M -$21.02M
YoY Change
Income Tax $0.00
% Of Pretax Income
Net Earnings -$20.74M -$21.02M -$11.32M
YoY Change 41.83% 85.72%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$405.7K -$413.0K
COMMON SHARES
Basic Shares Outstanding 50.95M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $386.2M $397.0M
YoY Change
Cash & Equivalents $386.2M $397.0M $33.32M
Short-Term Investments
Other Short-Term Assets $2.800M $3.800M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $389.0M $400.8M
YoY Change 530.24%
LONG-TERM ASSETS
Property, Plant & Equipment $3.272M $2.539M
YoY Change -3.51%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $550.0K $442.0K
YoY Change -5.82%
Total Long-Term Assets $3.822M $2.981M
YoY Change -3.85%
TOTAL ASSETS
Total Short-Term Assets $389.0M $400.8M
Total Long-Term Assets $3.822M $2.981M
Total Assets $392.8M $403.8M
YoY Change 497.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $29.79M $10.69M
YoY Change 782.26%
Accrued Expenses $3.766M $2.870M
YoY Change 188.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $46.86M $39.61M
YoY Change 324.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $112.0K $128.0K
YoY Change -53.72%
Total Long-Term Liabilities $112.0K $128.0K
YoY Change -53.72%
TOTAL LIABILITIES
Total Short-Term Liabilities $46.86M $39.61M
Total Long-Term Liabilities $112.0K $128.0K
Total Liabilities $46.98M $39.74M
YoY Change 299.48%
SHAREHOLDERS EQUITY
Retained Earnings -$198.6M -$177.8M
YoY Change 81.59%
Common Stock $544.4M $541.9M
YoY Change 18205.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $345.8M $364.1M -$92.16M
YoY Change
Total Liabilities & Shareholders Equity $392.8M $403.8M
YoY Change 497.93%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$20.74M -$21.02M -$11.32M
YoY Change 41.83% 85.72%
Depreciation, Depletion And Amortization $340.0K $330.0K
YoY Change -46.03%
Cash From Operating Activities -$10.77M -$13.05M
YoY Change -54.88%
INVESTING ACTIVITIES
Capital Expenditures -$730.0K -$30.00K
YoY Change -28.43%
Acquisitions
YoY Change
Other Investing Activities $0.00 $50.00K
YoY Change
Cash From Investing Activities -$730.0K $20.00K
YoY Change -28.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 550.0K 40.00K
YoY Change -98.68%
NET CHANGE
Cash From Operating Activities -10.77M -13.05M
Cash From Investing Activities -730.0K 20.00K
Cash From Financing Activities 550.0K 40.00K
Net Change In Cash -10.95M -12.99M
YoY Change -165.06%
FREE CASH FLOW
Cash From Operating Activities -$10.77M -$13.05M
Capital Expenditures -$730.0K -$30.00K
Free Cash Flow -$10.04M -$13.02M
YoY Change -56.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94404
dei Local Phone Number
LocalPhoneNumber
837-0111
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
50949711
dei City Area Code
CityAreaCode
650
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
39612000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11052000
CY2020Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1000
CY2019Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
17000
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
54000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
541848000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2967000
dei Amendment Flag
AmendmentFlag
false
dei Entity File Number
EntityFileNumber
001-39323
dei Entity Address Address Line1
EntityAddressAddressLine1
353 Hatch Drive
dei Entity Central Index Key
EntityCentralIndexKey
0001649094
CY2020Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.593
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4233385
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58976000
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address City Or Town
EntityAddressCityOrTown
Foster City
dei Entity Registrant Name
EntityRegistrantName
VAXCYTE, INC.
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
PCVX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
397048000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3787000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2747000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
400835000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
61723000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2539000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3391000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
442000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
584000
CY2020Q3 us-gaap Assets
Assets
403816000
CY2019Q4 us-gaap Assets
Assets
65698000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
10685000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3376000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1490000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
414000
CY2020Q3 pcvx Accrued Manufacturing Expenses
AccruedManufacturingExpenses
24540000
CY2019Q4 pcvx Accrued Manufacturing Expenses
AccruedManufacturingExpenses
5777000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2870000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1305000
CY2020Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
27000
CY2019Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
19000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
161000
CY2019Q4 pcvx Redeemable Convertible Preferred Stock Warrant Liability
RedeemableConvertiblePreferredStockWarrantLiability
450000
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
128000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
242000
CY2020Q3 us-gaap Liabilities
Liabilities
39741000
CY2019Q4 us-gaap Liabilities
Liabilities
11761000
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-132966000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-177827000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109347000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
364075000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-106373000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
403816000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
65698000
CY2020Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
134000
CY2019Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
15000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
52000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50949490
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4059909
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50949490
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4059909
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16410000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9630000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58903000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32225000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4898000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2510000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11225000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6089000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
21308000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
12140000
us-gaap Operating Expenses
OperatingExpenses
70128000
us-gaap Operating Expenses
OperatingExpenses
38314000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21308000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12140000
us-gaap Operating Income Loss
OperatingIncomeLoss
-70128000
CY2019Q3 us-gaap Interest Expense
InterestExpense
9000
us-gaap Interest Expense
InterestExpense
7000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
33000
CY2019Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
120000
CY2020Q3 pcvx Grant Income
GrantIncome
787000
CY2019Q3 pcvx Grant Income
GrantIncome
54000
pcvx Grant Income
GrantIncome
54000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-709000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-417000
CY2019Q3 pcvx Change In Fair Value Of Redeemable Convertible Preferred Stock
ChangeInFairValueOfRedeemableConvertiblePreferredStock
844000
pcvx Change In Fair Value Of Redeemable Convertible Preferred Stock
ChangeInFairValueOfRedeemableConvertiblePreferredStock
2520000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38314000
us-gaap Interest Expense
InterestExpense
33000
us-gaap Investment Income Interest
InvestmentIncomeInterest
212000
us-gaap Investment Income Interest
InvestmentIncomeInterest
537000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
372000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-27142000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-57728000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
823000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1648000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2661000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-21018000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-11317000
us-gaap Net Income Loss
NetIncomeLoss
-68480000
us-gaap Net Income Loss
NetIncomeLoss
-35653000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.93
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.06
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.54
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
50895358
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3857298
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22354212
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3737779
CY2020Q3 pcvx Research And Development Expense To Related Party
ResearchAndDevelopmentExpenseToRelatedParty
143000
CY2019Q3 pcvx Research And Development Expense To Related Party
ResearchAndDevelopmentExpenseToRelatedParty
1011000
pcvx Research And Development Expense To Related Party
ResearchAndDevelopmentExpenseToRelatedParty
458000
pcvx Research And Development Expense To Related Party
ResearchAndDevelopmentExpenseToRelatedParty
1123000
CY2020Q1 pcvx Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
128000
CY2020Q2 pcvx Temporary Equity Conversion Of Preferred Stock Value
TemporaryEquityConversionOfPreferredStockValue
270190000
CY2020Q2 pcvx Adjustments To Additional Paid In Capital Warrant Liability Write Off
AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff
629000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
264079000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
297000
CY2020Q2 pcvx Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
12000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1289000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-20320000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
383210000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
108000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
72000
CY2019Q1 pcvx Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
20000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
266000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-13671000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-71113000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
278000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-10665000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-81478000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
314000
CY2019Q3 pcvx Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
55000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
266000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-92160000
us-gaap Profit Loss
ProfitLoss
-68480000
us-gaap Profit Loss
ProfitLoss
-35653000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1073000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
900000
us-gaap Share Based Compensation
ShareBasedCompensation
3499000
us-gaap Share Based Compensation
ShareBasedCompensation
810000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
179000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-12000
pcvx Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liabilities
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities
2520000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-32000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-1000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
267000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1040000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1071000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-33000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-10000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7330000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1190000
pcvx Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
1076000
pcvx Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
-283000
pcvx Increase Decrease In Accrued Manufacturing Expenses
IncreaseDecreaseInAccruedManufacturingExpenses
18763000
pcvx Increase Decrease In Accrued Manufacturing Expenses
IncreaseDecreaseInAccruedManufacturingExpenses
4585000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1416000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1605000
pcvx Increase Decrease In Deferred Rent And Other Long Term Liabilities
IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities
-8000
pcvx Increase Decrease In Deferred Rent And Other Long Term Liabilities
IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities
79000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35860000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32739000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
433000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
242000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
50000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-383000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-242000
pcvx Payments Of Capital Lease Obligations
PaymentsOfCapitalLeaseObligations
61000
pcvx Payments Of Capital Lease Obligations
PaymentsOfCapitalLeaseObligations
220000
pcvx Proceeds From Initial Public Offering Net Of Underwriters Commissions And Discounts
ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts
267375000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3368000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
109879000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
454000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
315000
pcvx Proceeds From Issuance Of Common Stock Related To Early Exercised Stock Options
ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions
36000
pcvx Proceeds From Issuance Of Common Stock Related To Early Exercised Stock Options
ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions
120000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
374315000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
215000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
338072000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-32766000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58976000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66090000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
397048000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33324000
us-gaap Interest Paid Net
InterestPaidNet
7000
us-gaap Interest Paid Net
InterestPaidNet
33000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
149000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
197000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
270190000
pcvx Issuance Costs For Initial Public Offering Included In Accounts Payable And Accrued Expenses
IssuanceCostsForInitialPublicOfferingIncludedInAccountsPayableAndAccruedExpenses
17000
pcvx Issuance Costs For Initial Public Offering Included In Accounts Payable And Accrued Expenses
IssuanceCostsForInitialPublicOfferingIncludedInAccountsPayableAndAccruedExpenses
602000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities at the date of the financial statements. On an ongoing basis, we evaluate our estimates and assumptions, including those related to stock-based compensation expense, accruals for certain research and development costs, the valuation of deferred tax assets and income taxes. Management bases our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates. </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject us to a concentration of credit risk consist primarily of cash and cash equivalents. We currently invest in money market funds. We maintain bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash and cash equivalents. We have not experienced any losses on our deposits of cash and cash equivalents.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to supplier concentration risk from our suppliers. We source our critical raw materials from a sole source supplier, Sutro Biopharma, Inc. (&#8220;Sutro Biopharma&#8221;). We also use one contract manufacturing organization (&#8220;CMO&#8221;), Lonza Ltd. (&#8220;Lonza&#8221;), to handle most of our manufacturing activities. If we were to experience disruptions in raw materials supplied by Sutro Biopharma, or in manufacturing activities at Lonza, we may experience significant delays in our product development timelines and may incur substantial costs to secure alternative sources of raw materials or manufacturing.&nbsp;&nbsp;</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future results of operations involve a number of other risks and uncertainties. Factors that could affect our future operating results and cause actual results to vary materially from expectations include, but are not limited to, our early stages of clinical vaccine development; our ability to advance vaccine candidates into, and successfully complete, clinical trials on the timelines we project; our ability to adequately demonstrate sufficient safety and efficacy of our vaccine candidates; our ability to enroll subjects in our ongoing and future clinical trials; our ability to successfully manufacture and supply our vaccine candidates for clinical trials; our ability to obtain additional capital to finance our operations; our ability to obtain, maintain and protect our intellectual property rights; developments relating to our competitors and our industry, including competing vaccine candidates; general and market conditions; and other risks and uncertainties, including those more fully described in the &#8220;Risk Factors&#8221; section of this Quarterly Report on Form 10-Q.</p>
CY2019Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2020Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2982000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2020Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2020Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6370000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6373000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3831000
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1100000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
CY2020Q3 us-gaap Capital Leases Income Statement Amortization Expense
CapitalLeasesIncomeStatementAmortizationExpense
0
CY2019Q3 us-gaap Capital Leases Income Statement Amortization Expense
CapitalLeasesIncomeStatementAmortizationExpense
100000
us-gaap Capital Leases Income Statement Amortization Expense
CapitalLeasesIncomeStatementAmortizationExpense
200000
CY2020Q3 pcvx Accrued Preclinical Studies Current
AccruedPreclinicalStudiesCurrent
1969000
CY2019Q4 pcvx Accrued Preclinical Studies Current
AccruedPreclinicalStudiesCurrent
844000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
486000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
397000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
415000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
64000
CY2020Q3 us-gaap Lessee Finance Lease Term Of Contract1
LesseeFinanceLeaseTermOfContract1
P36M
pcvx Percentage Of Annual Rental Payments Including Guaranteed Residual Value
PercentageOfAnnualRentalPaymentsIncludingGuaranteedResidualValue
0.90
CY2020Q1 pcvx Number Of Lab Equipment
NumberOfLabEquipment
2
CY2019Q4 pcvx Number Of Lab Equipment
NumberOfLabEquipment
2
CY2020Q3 us-gaap Other Commitments Future Minimum Payments Remainder Of Fiscal Year
OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear
0
CY2020Q3 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
0
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P30M
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
In July 2016, we entered into a five-year lease agreement for our headquarters facility located in Foster City, California. The term of the lease is from September 1, 2016 to August 31, 2021, with two 30-month renewal options.
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
183000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
531000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
714000
CY2020Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
200000
CY2019Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
200000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
500000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
35962362
CY2019Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
20390095
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
20390095
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
160310000
CY2019Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
172037000
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2019 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote.
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
66982
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
91133
CY2020Q3 pcvx Early Exercised Stock Options
EarlyExercisedStockOptions
22700
CY2019Q4 pcvx Early Exercised Stock Options
EarlyExercisedStockOptions
86409
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
66982
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
29.83
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.17
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.51
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2500000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2020Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
67792
CY2019Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
279947
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
263626
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
280836
CY2020Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.60
CY2019Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.55
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.86
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.55
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.930
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.802
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.812
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.784
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.935
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.804
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.935
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.804
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.003
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.016
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.003
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.016
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.018
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.014
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.024
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21018000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11317000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-68480000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35653000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5094669
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19863546
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0001564590-20-053540-index-headers.html Edgar Link pending
0001564590-20-053540-index.html Edgar Link pending
0001564590-20-053540.txt Edgar Link pending
0001564590-20-053540-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pcvx-10q_20200930.htm Edgar Link pending
pcvx-20200930.xml Edgar Link completed
pcvx-20200930.xsd Edgar Link pending
pcvx-20200930_cal.xml Edgar Link unprocessable
pcvx-20200930_def.xml Edgar Link unprocessable
pcvx-20200930_lab.xml Edgar Link unprocessable
pcvx-20200930_pre.xml Edgar Link unprocessable
pcvx-ex311_7.htm Edgar Link pending
pcvx-ex312_6.htm Edgar Link pending
pcvx-ex321_9.htm Edgar Link pending
pcvx-ex322_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending